Crystal Bioscience Partners with Genexis to Discover Bio and Healthcare Startups

[Asia Economy Reporter Lee Gwan-joo] Crystal Bioscience and accelerator 'Genexis' announced on the 18th that they will jointly conduct the bio-healthcare startup batch program 'Finding BIO.'

Finding BIO is a startup batch program that discovers promising startups that will create new innovations in the bio-healthcare industry and provides focused nurturing and investment. Both companies plan to support systematic growth by leveraging their accumulated expertise in the bio-healthcare field.

Crystal Bioscience is a new technology business finance company that discovers and invests in startups based on differentiated technology and aims for strategic cooperation such as licensing and open innovation with its parent company, Crystal Genomics. It specializes in cross-border deals and actively invests in domestic and international innovative new drugs (First-in-class), as well as smart healthcare and bioinformatics (life sciences).

Genexis is an accelerator that discovers, nurtures, and invests in promising early-stage bio-healthcare startups. Based on a global network encompassing in-house personnel with bio-healthcare expertise, healthcare industry experts, bio venture founders, domestic and international investors, research institutions, and pharmaceutical companies, it accelerates the value-up of startups. It invests not only in pure new drug bio fields but also in the entire medical industry where 4th industrial revolution technologies converge, such as medical innovation services, digital healthcare, and medical artificial intelligence.

Applications for the first batch of Finding BIO are open until the 15th of next month. The recruitment fields include all areas of bio-healthcare, including innovative new drugs, digital healthcare, such as bio new drugs, diagnostics, medical devices, digital therapeutics, medical service platforms, and age-friendly innovations. Extra points will be given to companies located in provincial areas.

A Crystal Bioscience official emphasized, "We will finally select a total of five companies this time and directly invest up to 1 billion KRW per excellent graduating company," adding, "We provide various benefits such as IR consulting, customized mentoring for each new drug development cycle by experts in research and development and business plan establishment and execution, and support for follow-up investment attraction utilizing affiliated company infrastructure."

This content was produced with the assistance of AI translation services.